BioCentury | Nov 14, 2020
Politics, Policy & Law

U.K.’s opportunity as changes come to MHRA, NICE

...attractive to industry.” Paul Catchpole, ABPI The National Institute for Health and Care Excellence (NICE)...
...most of the next year to complete. Stephen Hansen National Institute for Health and Care Excellence (NICE) MHRA U.K...
BioCentury | Apr 10, 2020
Politics, Policy & Law

Piloting a new course to reimbursing antibiotics

...announce the start of its procurement process soon; it will run through 2022. Stephen Hansen, Associate Editor National Institute for Health and Care Excellence (NICE) NHS...
BioCentury | Mar 19, 2020
Management Tracks

Leng will become NICE chief executive; plus BMS, Sofinnova, Medicxi, PTC, Orchard and more

...clinical R&D, and Mark O'Mahony to chief manufacturing officer from VP of manufacturing. Robin Sawka, BioCentury Staff National Institute for Health and Care Excellence (NICE) NeoPhore...
BioCentury | Mar 5, 2020
Politics, Policy & Law

NICE not ready to put patient preference into reimbursement decisions

...In an article published January in The Patient - Patient-Centered Outcomes Research , the U.K.’s National Institute for Health and Care Excellence (NICE)...
...said it has no “planned activities” regarding future studies of patient preference data. Inhua Muijrers-Chen, Associate Editor National Institute for Health and Care Excellence (NICE) Novartis...
BioCentury | Oct 11, 2019
Company News

Oct. 11 Company Quick Takes: FDA approves Lilly migraine drug; plus Clovis, Evotec-Celmatix, Avacta-ADC and Neumentum-J&J

...AG-014699 (Former compound #), rucaparib (Generic) oral lasmiditan (LY573144, Oral COL-144, IY573144) Avacta Group plc Celmatix Inc. Clovis Oncology Inc. National Institute for Health and Care Excellence (NICE) Eli...
BioCentury | Oct 4, 2019
Clinical News

Summit’s C. diff benefits for ridinilazole continue with early, sustained effect on quality of life

...the estimated primary completion date is September 2021. Inhua Muijrers-Chen, Associate Editor Ridinilazole (smt19969, SMT 19969) Summit Therapeutics Inc. National Institute for Health and Care Excellence (NICE)...
BioCentury | Sep 13, 2019
Company News

Vertex reaches CF deal in Scotland

...Scotland’s. Inhua Muijrers-Chen, Associate Editor Orkambi (Brand), ivacaftor/VX-809 (Generic), ivacaftor/lumacaftor (Generic), Orkambi (Other) Symdeko, Symkevi, tezacaftor/ivacaftor, tezacaftor (VX-661)/ivacaftor, Tez/Iva National Institute for Health and Care Excellence (NICE) NHS...
BioCentury | Sep 4, 2019
Company News

Novartis’ early collaboration with NICE key to rapid response on Luxturna

...or 28 weeks (see " NICE Recommends Strimvelis "). Erin McCallister, Senior Editor AAV2-hRPE65v2, Luxturna, voretigene neparvovec-rzyl (spk-rpe65) National Institute for Health and Care Excellence (NICE) Novartis...
BioCentury | Aug 31, 2019
Product Development

Digital health: payers are figuring out what it’s worth

...but could not provide comment in time for publication. The U.K. is furthest ahead. Its National Institute for Health and Care Excellence (NICE)...
...accurate and reliable measurement and transmission of the data. Table: NICE digital evidence The U.K.’s National Institute for Health and Care Excellence (NICE)...
...Mass. National Institute for Health and Care Excellence (NICE), London, U.K. NHS England, London, U.K. Pear Therapeutics Inc., Boston, Mass. Erin McCallister, Senior Editor National Institute for Health and Care Excellence (NICE) Harvard...
BioCentury | Aug 23, 2019
Company News

Aug. 22 Company Quick Takes: Innovent, Lilly in biologics deal; plus Sobi, Gilead, Themis-Merck, Iconic-Novartis, GW, BeiGene, Clearside, Inex Innovations

...thromboplastin) - Tissue factor BioCentury Staff Epidiolex, Epidyolex, cannabidiol Eli Lilly and Co. Gilead Sciences Inc. GW Pharmaceuticals plc Innovent Biologics Inc. National Institute for Health and Care Excellence (NICE) Swedish...
Items per page:
1 - 10 of 57
BioCentury | Nov 14, 2020
Politics, Policy & Law

U.K.’s opportunity as changes come to MHRA, NICE

...attractive to industry.” Paul Catchpole, ABPI The National Institute for Health and Care Excellence (NICE)...
...most of the next year to complete. Stephen Hansen National Institute for Health and Care Excellence (NICE) MHRA U.K...
BioCentury | Apr 10, 2020
Politics, Policy & Law

Piloting a new course to reimbursing antibiotics

...announce the start of its procurement process soon; it will run through 2022. Stephen Hansen, Associate Editor National Institute for Health and Care Excellence (NICE) NHS...
BioCentury | Mar 19, 2020
Management Tracks

Leng will become NICE chief executive; plus BMS, Sofinnova, Medicxi, PTC, Orchard and more

...clinical R&D, and Mark O'Mahony to chief manufacturing officer from VP of manufacturing. Robin Sawka, BioCentury Staff National Institute for Health and Care Excellence (NICE) NeoPhore...
BioCentury | Mar 5, 2020
Politics, Policy & Law

NICE not ready to put patient preference into reimbursement decisions

...In an article published January in The Patient - Patient-Centered Outcomes Research , the U.K.’s National Institute for Health and Care Excellence (NICE)...
...said it has no “planned activities” regarding future studies of patient preference data. Inhua Muijrers-Chen, Associate Editor National Institute for Health and Care Excellence (NICE) Novartis...
BioCentury | Oct 11, 2019
Company News

Oct. 11 Company Quick Takes: FDA approves Lilly migraine drug; plus Clovis, Evotec-Celmatix, Avacta-ADC and Neumentum-J&J

...AG-014699 (Former compound #), rucaparib (Generic) oral lasmiditan (LY573144, Oral COL-144, IY573144) Avacta Group plc Celmatix Inc. Clovis Oncology Inc. National Institute for Health and Care Excellence (NICE) Eli...
BioCentury | Oct 4, 2019
Clinical News

Summit’s C. diff benefits for ridinilazole continue with early, sustained effect on quality of life

...the estimated primary completion date is September 2021. Inhua Muijrers-Chen, Associate Editor Ridinilazole (smt19969, SMT 19969) Summit Therapeutics Inc. National Institute for Health and Care Excellence (NICE)...
BioCentury | Sep 13, 2019
Company News

Vertex reaches CF deal in Scotland

...Scotland’s. Inhua Muijrers-Chen, Associate Editor Orkambi (Brand), ivacaftor/VX-809 (Generic), ivacaftor/lumacaftor (Generic), Orkambi (Other) Symdeko, Symkevi, tezacaftor/ivacaftor, tezacaftor (VX-661)/ivacaftor, Tez/Iva National Institute for Health and Care Excellence (NICE) NHS...
BioCentury | Sep 4, 2019
Company News

Novartis’ early collaboration with NICE key to rapid response on Luxturna

...or 28 weeks (see " NICE Recommends Strimvelis "). Erin McCallister, Senior Editor AAV2-hRPE65v2, Luxturna, voretigene neparvovec-rzyl (spk-rpe65) National Institute for Health and Care Excellence (NICE) Novartis...
BioCentury | Aug 31, 2019
Product Development

Digital health: payers are figuring out what it’s worth

...but could not provide comment in time for publication. The U.K. is furthest ahead. Its National Institute for Health and Care Excellence (NICE)...
...accurate and reliable measurement and transmission of the data. Table: NICE digital evidence The U.K.’s National Institute for Health and Care Excellence (NICE)...
...Mass. National Institute for Health and Care Excellence (NICE), London, U.K. NHS England, London, U.K. Pear Therapeutics Inc., Boston, Mass. Erin McCallister, Senior Editor National Institute for Health and Care Excellence (NICE) Harvard...
BioCentury | Aug 23, 2019
Company News

Aug. 22 Company Quick Takes: Innovent, Lilly in biologics deal; plus Sobi, Gilead, Themis-Merck, Iconic-Novartis, GW, BeiGene, Clearside, Inex Innovations

...thromboplastin) - Tissue factor BioCentury Staff Epidiolex, Epidyolex, cannabidiol Eli Lilly and Co. Gilead Sciences Inc. GW Pharmaceuticals plc Innovent Biologics Inc. National Institute for Health and Care Excellence (NICE) Swedish...
Items per page:
1 - 10 of 57